Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases

Pathobiology

Volumn 74, Issue 2, 2007, Pages 97-114

  Orazi, Attilio ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acute myeloid leukemia; Histopathology; Myelodysplastic syndromes; Myeloproliferative disorders

Indexed keywords

CD103 ANTIGEN; CD163 ANTIGEN; CD2 ANTIGEN; CD20 ANTIGEN; CD3 ANTIGEN; CD34 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CD61 ANTIGEN; CD68 ANTIGEN; CD7 ANTIGEN; CD79A ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; DOXORUBICIN; ETOPOSIDE; GLYCOPROTEIN IB ALPHA; HEMOGLOBIN; LYSOZYME; MYELOPEROXIDASE; T6 ANTIGEN; TENIPOSIDE; TRANSCRIPTION FACTOR GATA 1; TRANSCRIPTION FACTOR PAX5;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE MEGAKARYOCYTIC LEUKEMIA; BIOACCUMULATION; BONE MARROW BIOPSY; CYTOGENETICS; DISEASE CLASSIFICATION; FLOW CYTOMETRY; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MYELODYSPLASTIC SYNDROME; MYELOID LEUKEMIA; MYELOPROLIFERATIVE DISORDER; PRIORITY JOURNAL; REVIEW;

ACUTE DISEASE; ANTIGENS, CD34; ANTINEOPLASTIC AGENTS; BIOPSY; BONE MARROW; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOHISTOCHEMISTRY; LEUKEMIA, MEGAKARYOCYTIC, ACUTE; LEUKEMIA, MYELOID; MYELODYSPLASTIC SYNDROMES; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDERS; PROGNOSIS; RETICULIN;

CUCURBITA;

EID: 34250863880     PISSN: 10152008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000101709     Document Type: Review

References (59)

1. Orazi A, O'Malley DP, Arber D: Illustrated Pathology of the Bone Marrow. New York, Cambridge University Press, 2006.
2. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C: Proposals for the classification of the acute leukemias. Br J Haematol 1976;33:451-458.
3. Lu G, Altman AJ, Benn PA: Review of the cytogenetic changes in acute megakaryoblastic leukemia: one disease or several? Cancer Genet Cytogenet 1993;67:81-89.
4. Lion T, Haas OA, Harbott J, Bannier E, Ritterbach J, Jankovic M, Fink FM, Stojimirovic A, Herrmann J, Riehm HJ: The translocation t(1;22)(p13;q13) is a nonrandom marker specifically associated with acute megakaryocytic leukemia in young children. Blood 1992;79:3325-3330.
5. Orazi A, Neiman RS, Ulbright TM, Heerema NA, John K, Nichols CR: Hematopoietic precursor cells within the yolk sac tumor component are the source of secondary hematopoietic malignancies in patients with mediastinal germ cell tumors. Cancer 1993;71:3873-3881.
6. Orazi A, O'Malley DP, Jiang J, Vance GH, Thomas J, Czader MB, Fang W, An C, Banks PM: Acute panmyelosis with myelofibrosis: an entity distinct from acute megakaryoblastic leukemia. Mod Pathol 2005;18:603-614.
7. Thiele J, Kvasnicka HM, Zerhusen G, Vardiman J, Diehl V, Luebbert M, Schmitt-Graeff A: Acute panmyelosis with myelofibrosis: a clinicopathological study on 46 patients including histochemistry of bone marrow biopsies and follow-up. Ann Hematol 2004;83:513-521.
8. Gahn B, Haase D, Unterhalt M, Drescher M, Schoch C, Fonatsch C, Terstappen LW, Hiddemann W, Buchner T, Bennett JM, Wormann B: De novo AML with dysplastic hematopoiesis: cytogenetic and prognostic significance. Leukemia 1996;10:946-951.
9. Brunning RD, Matutes E, Harris NL, Flandrin G, Vardiman J, Bennett J, Head D: Acute myeloid leukaemia with multilineage dysplasia;in Jaffe ES, Harris NL, Stein H, Var diman JW (eds): World Health Organization Classification of Tumors: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, IARC Press, 2001, pp 88-89.
10. Orazi A, Cattoretti G, Soligo D, Luksch R, Lambertenghi-Deliliers G: Therapy-related myelodysplastic syndromes: FAB classification, bone marrow histology, and immunohistology in the prognostic assessment. Leukemia 1993;7:838-847.
11. Arber DA, Stein AS, Carter NH, Ikle D, Forman SJ, Slovak MLL: Prognostic impact of acute myeloid leukemia classification. Importance of detection of recurring cytogenetic abnormalities and multilineage dysplasia on survival. Am J Clin Pathol 2003;119:672-680.
12. Pedersen-Bjergaard J, Andersen MK, Christiansen DH: Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation. Blood 2000;95:3273-3279.
13. Rowley JD, Olney HJ: International Workshop on the Relationship of Prior Therapy to Balanced Chromosome Aberrations in Therapy-Related Myelodysplastic Syndromes and Acute Leukemia: Overview report. Genes Chromosomes Cancer 2002;33:331-345.
14. Lambertenghi-Deliliers G, Annaloro C, Soligo D, Oriani A: The diagnostic and prognostic value of bone marrow immunostaining in myelodysplastic syndromes. Leuk Lymphoma 1998;28:231-239.
15. Verburgh E, Achten R, Maes B, Hagemeijer A, Boogaerts M, De Wolf-Peeters C, Verhoef G: Additional prognostic value of bone marrow histology in patients subclassified according to the International Prognostic Scoring System for myelodysplastic syndromes. J Clin Oncol 2003;21:273-282.
16. Tricot G, De Wolf-Peeters C, Vlietinck R, Verwilghen RL: Bone marrow histology in myelodysplastic syndromes. II. Prognostic value of abnormal localization of immature precursors in MDS. Br J Haematol 1984;58:217-225.
17. De Wolf-Peeters C, Stessens R, Desmet V, Tricot G, Verwilghen RL: The histological characterization of ALIP in the myelodysplastic syndromes. Pathol Res Pract 1986;181:402-407.
18. Orazi A: CD34 immunoperoxidase staining for the diagnosis of myelodysplastic syndromes and chronic myeloid leukaemia. J Clin Pathol 1995;48:884.
19. Soligo DA, Oriani A, Annaloro C, Cortelezzi A, Calori R, Pozzoli E, Nosella D, Orazi A, Deliliers GL: CD34 immunohistochemistry of bone marrow biopsies: prognostic significance in primary myelodysplastic syndromes. Am J Hematol 1994;46:9-17.
20. Baur AS, Meuge-Moraw C, Schmidt PM, Parlier V, Jotterand M, Delacretaz F: CD34/ QBEND10 immunostaining in bone marrow biopsies: an additional parameter for the diagnosis and classification of myelodysplastic syndromes. Eur J Haematol 2000;64:71-79.
21. Pellegrini W, Facchetti F, Marocolo D, Pelizzari AM, Capucci A, Rossi G: Expression of CD34 by megakaryocytes in myelodysplastic syndromes. Haematologica 2000;85:1117-1118.
22. Lambertenghi-Deliliers G, Orazi A, Luksch R, Annaloro C, Soligo D: Myelodysplastic syndrome with increased marrow fibrosis: a distinct clinico-pathological entity. Br J Haematol 1991;78:161-166.
23. Neiman RS: Erythroblastic transformation in myeloproliferative disorders: confirmation by an immunohistologic technique. Cancer 1980;46:1636-1640.
24. Pinkus GS, Pinkus JL: Myeloperoxidase: a specific marker for myeloid cells in paraffin sections. Mod Pathol 1991;4:733-741.
25. Manaloor EJ, Neiman RS, Heilman DK, Albitar M, Casey T, Vattuone T, Kotylo P, Orazi A: Immunohistochemistry can be used to subtype acute myeloid leukemia in routinely processed bone marrow biopsy specimens. Comparison with flow cytometry. Am J Clin Pathol 2000;113:814-822.
26. Orazi A, Chiu R, O'Malley DP, Czader M, Allen SL, An C, Vance GH: Chronic myelomonocytic leukemia: the role of bone marrow biopsy immunohistology. Mod Pathol 2006;19:1536-1545.
27. Maschek H, Georgii A, Kaloutski V, Werner M, Bandecar K, Kressel MG, Choritz H, Freund M, Hufnagl D: Myelofibrosis in primary myelodysplastic syndromes: a retrospective study of 352 patients. Eur J Haematol 1992;48:208-214.
28. Pagliuca A, Layton DM, Manoharan A, Gordon S, Green PJ, Mufti GJ: Myelofibrosis in primary myelodysplastic syndromes: a clinico-morphological study of 10 cases. Br J Haematol 1989;71:499-504.
29. Levine EG, Bloomfield CD: Leukemias and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure. Semin Oncol 1992;19:47-84.
30. Orazi A, Cattoretti G, Heerema NA, Sozzi G, John K, Neiman RS: Frequent p53 overexpression in therapy-related myelodysplastic syndromes and acute myeloid leukemias: an immunohistochemical study of bone marrow biopsies. Mod Pathol 1993;6:521-525.
31. Orazi A, Albitar M, Heerema NA, Haskins S, Neiman RS: Hypoplastic myelodysplastic syndromes can be distinguished from acquired aplastic anemia by CD34 and PCNA immunostaining of bone marrow biopsy specimens. Am J Clin Pathol 1997;107:268-274.
32. Maschek H, Kaloutsi V, Rodriguez-Kaiser M, Werner M, Choritz H, Mainzer K, Dietzfelbinger M, Georgii A: Hypoplastic myelodysplastic syndrome: incidence, morphology, cytogenetics, and prognosis. Ann Hematol 1993;66:117-122.
33. Orazi A, Kahsai M, John K, Neiman RS: p53 overexpression in myeloid leukemic disorders is associated with increased apoptosis of hematopoietic marrow cells and ineffective hematopoiesis. Mod Pathol 1996;9:48-52.
34. Ponzoni M, Savage DG, Ferreri AJM, Pruneri G, Viale G, Servida P, Bertolini F, Orazi A: Chronic idiopathic myelofibrosis: independent prognostic importance of bone marrow microvascular density evaluated by CD105 (endoglin) immunostaining. Mod Pathol 2004;17:1513-1520.
35. Molica S, Vacca A, Levato D, Merchionne F, Ribatti D: Angiogenesis in acute and chronic lymphoblastic leukemia. Leuk Res 2004;28:321-324.
36. Pruneri G, Bertolini F, Soligo D, Carboni N, Cortelezzi A, Ferrucci PF, Buffa R, Lambertenghi-Deliliers G, Pezzella F: Angiogenesis in myelodysplastic syndromes. Br J Cancer 1999;81:1398-1401.
37. Manoharan A, Horsley R, Pitney WR: The reticulin content of bone marrow in acute leukaemia in adults. Br J Haematol 1979;43:185-190.
38. Pedersen-Bjergaard J, Philip P, Larsen SO, Andersson M, Daugaard G, Ersboll J, Hansen SW, Hou-Jensen K, Nielsen D, Sigsgaard TC, et al: Therapy-related myelodysplasia and acute myeloid leukemia. Cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in the Copenhagen series. Leukemia 1993;7:1975-1986.
39. Ellis M, Ravid M, Lishner M: A comparative analysis of alkylating agent and epipodophyllotoxin-related leukemias. Leuk Lymphoma 1993;11:9-13.
40. Michels SD, McKenna RW, Arthur DC, Brunning RD: Therapy-related acute myeloid leukemia and myelodysplastic syndrome: a clinical and morphologic study of 65 cases. Blood 1985;65:1364-1372.
41. Quesnel B, Kantarjian H, Bjergaard JP, Brault P, Estey E, Lai JL, Tilly H, Stoppa AM, Archimbaud E, Harousseau JL, et al: Therapy-related acute myeloid leukemia with t(8;21), inv(16), and t(8;16): a report on 25 cases and review of the literature. J Clin Oncol 1993;11:2370-2379.
42. Lai JL, Preudhomme C, Zandecki M, Flactif M, Vanrumbeke M, Lepelley P, Wattel E, Fenaux P: Myelodysplastic syndromes and acute myeloid leukemia with 17-p deletion. An entity characterized by specific dysgranulopoiesis and a high incidence of p53 mutations. Leukemia 1995;9:370-381.
43. Sugimoto K, Hirano N, Toyoshima H, Chiba S, Mano H, Takaku F, Yazaki Y, Hirai H: Mutations of the p53 gene in myelodysplastic syndrome (MDS) and MDS-derived leukemia. Blood 1993;81:3022-3026.
44. Tuzuner N, Cox C, Rowe JM, Watrous D, Bennett JM: Hypocellular myelodysplastic syndromes: new proposals. Br J Haematol 1995;91:612-617.
45. Matsui WH, Brodsky RA, Smith BD, Borowitz MJ, Jones RJ: Quantitative analysis of bone marrow CD34 cells in aplastic anemia and hypoplastic myelodysplastic syndromes. Leukemia 2006;20:458-462.
46. Goyal R, Qawi H, Ali I, Dar S, Mundle S, Shetty V, Mativi Y, Allampallam K, Lisak L, Loew J, Venugopal P, Gezer S, Robin E, Rifkin S, Raza A: Biologic characteristics of patients with hypocellular myelodysplastic syndromes. Leuk Res 1999;23:357-364.
47. Barrett J, Saunthararajah Y, Molldrem J: Myelodysplastic syndrome and aplastic anemia: distinct entities or diseases linked by a common pathophysiology? Semin Hematol 2000;37:15-29.
48. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick H, Sultan C, Cox C: The chronic myeloid leukemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukemia. Proposals by the French American-British Cooperative Leukemia Group. Br J Haematol 1994;87:746-754.
49. Oscier D: Atypical chronic myeloid leukemias. Pathol Biol (Paris) 1997;45:587-593.
50. Vardiman, JW, Imbert M, Pierre R, Bain B, Brunning RD, Flandrin G: Atypical chronic myeloid leukaemia;in Jaffe ES, Harris NL, Stein H, Vardiman JW (eds): World Health Organization Classification of Tumors: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, IARC Press, 2001, pp 53-54.
51. Martiat P, Michaux JL, Rodhain J: Philadelphia-negative (Ph-) chronic myeloid leukemia (CML): comparison with Ph+ CML and chronic myelomonocytic leukemia. Blood 1991;78:205-211.
52. Germing U, Gattermann N, Minning H, Heyll A, Aul C: Problems in the classification of CMML-dysplastic versus proliferative type. Leuk Res 1998;22:871-878.
53. Fenaux P, Beuscart R, Lai JL, Jouet JP, Bauters F: Prognostic factors in adult chronic myelomonocytic leukemia: an analysis of 107 cases. J Clin Oncol 1988;6:1417-1424.
54. Storniolo AM, Moloney WC, Rosenthal DS, Cox C, Bennett JM: Chronic myelomonocytic leukemia. Leukemia 1990;4:766-770.
55. Steer EJ, Cross NC: Myeloproliferative disorders with translocations of chromosome 5q31-35;role of the platelet-derived growth factor receptor β. Acta Haematol 2002;107:113-122.
56. Niemeyer CM, Kratz CP, Hasle H: Pediatric myelodysplastic syndromes. Curr Treat Options Oncol 2005;6:209-214.
57. Shaw GR: Ringed sideroblasts with thrombocytosis: an uncommon mixed myelodysplastic/myeloproliferative disease of older adults. Br J Haematol 2005;131:180-184.
58. Schmitt-Graeff A, Thiele J, Zuk I, Kvasnicka HM: Essential thrombocythemia with ringed sideroblasts: a heterogeneous spectrum of diseases, but not a distinct entity. Haematologica 2002;87:392-399.
59. Horny HP, Sotlar K, Sperr WR, Valent P: Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge. J Clin Pathol 2004;57:604-608.